GlassScriptPhysician profile
Naga Praneeth Raja
NPI 1043508757
$2,167.35
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,674 · 2020: $328 · 2021: $64.17 · 2022: $62.75 · 2023: $38.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $38.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $38.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $298.73 | 2019-2023 | Imbruvica |
| Novartis Pharmaceuticals Corporation | $212.04 | 2019-2022 | |
| Amgen INC. | $200.70 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $162.28 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $159.76 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $145.11 | 2019 | |
| Eisai INC. | $109.05 | 2019-2020 | |
| Seagen INC. | $82.79 | 2019-2020 | |
| Puma Biotechnology, INC. | $65.26 | 2019-2021 | |
| Pfizer INC. | $58.80 | 2019 | |
| Celgene Corporation | $53.89 | 2019 | |
| Genzyme Corporation | $49.59 | 2019-2020 | |
| Verastem, INC. | $47.06 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.41 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.04 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $45.94 | 2019 | |
| Tesaro, INC. | $43.51 | 2019 | |
| Exelixis INC. | $39.06 | 2019 | |
| Taiho Oncology, INC. | $38.06 | 2019-2020 | |
| Incyte Corporation | $33.13 | 2019-2020 | |
| Astellas Pharma US INC | $32.77 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $31.30 | 2020 | |
| Daiichi Sankyo INC. | $30.21 | 2019 | |
| Clovis Oncology, INC. | $28.25 | 2019-2020 | |
| Lilly USA, LLC | $27.23 | 2019 | |
| Foundation Medicine, INC. | $24.91 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $23.97 | 2019 | |
| Beigene USA, INC. | $17.84 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.66 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naga Praneeth Raja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.